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High-grade	 sarcomas	 are	 a	 heterogeneous	 group	 of	 aggressive	 tumors	 arising	 in	 bone	 and	 soft	
tissues.	They	are	usually	 treated	with	surgery	combined	 in	some	cases	with	chemotherapy.	Drugs	




Tumors	 grow	 within	 an	 intricate	 network	 of	 epithelial	 cells,	 vascular	 and	 lymphatic	 vessels,	
cytokines,	 chemokines	 and	 infiltrating	 immune	 cells.	 T-	 lymphocyte	 and	 antigen-presenting	 cells	
(APCs)	interactions	are	bi-directional	and	mediated	by	ligands	such	as	programmed	cell	death	ligand	
1	 (PD-L1)	 on	 APCs	 and	 PD1	 on	 lymphocytes.	 PD-L1	 is	 expressed	 also	 by	 several	 tumors.	 PD-1	
inhibitors	 such	as	pembrolizumab	or	nivolumab	have	been	approved	 for	many	 tumors	and	PD-L1	







Finally,	 another	 key	 element	 of	 the	 tumor	 microenvironment	 involves	 its	 vasculature.	 Tumor	
angiogenesis	 is	 related	 to	 suppression	 of	 T	 cell-mediated	 tumor	 rejection.	 There	 are	 numerous	
examples	that	demonstrate	a	simultaneous	activation	of	angiogenesis	and	immunosuppression.	The	










Sarcomas	are	a	heterogeneous	group	of	mesenchymal	neoplasmas	 that	 can	be	grouped	 into	 two	
general	 types,	 primary	 bone	 sarcoma	 and	 soft	 tissue	 sarcoma.	 Most	 frequent	 primary	 bone	
sarcomas	 include	 osteosarcoma,	 Ewing	 sarcoma	 and	 chondrosarcoma;	most	 frequent	 soft	 tissue	
sarcomas	include	synovial	sarcoma,	liposarcoma,	leiomyosarcoma,	and	angiosarcoma.	The	survival	
rate	 of	 sarcoma	patients	 increased	with	 the	 emergence	of	 effective	 chemotherapy	 regimens	 and	
the	 development	 of	 surgical	 techniques.	 However,	 metastasis	 still	 occurs	 in	 20%-55%	 of	 these	
patients,	and	it	remains	the	main	cause	of	death.	Efforts	have	been	made	in	the	last	twenty	years	to	
improve	survival	outcomes	of	sarcoma	patients,	but	changes	of	the	chemotherapy	drugs,	the	doses	
and	 the	 administration	 schemes	 did	 not	 significantly	 improve	 prognosis	 (1).	 Advanced	 treatment	
methods	 are	 urgently	 needed.	 Identification	 of	 effective	 prognostic	 factors	 is	 important	 to	 get	 a	





Almost	 constantly	 intramedullary,	 rarely	 it	may	originate	at	 the	bony	 surface.	Osteosarcoma	may	
sometimes	 presents	 with	 skip	 or	 more	 distant	 skeletal	 metastases,	 but	 it	 can	 be	 also	 skeletally	
multifocal	 at	 presentation.	 There	 are,	 consequently,	 several	 varieties	 of	 osteosarcoma	 whose	
anatomo-clinical	 presentation,	 treatment	 and	 prognosis,	 however,	 are	 not	 as	 distinctive	 as	 to	
		 10	
justify	a	separate	classification.	Other	low	grade	osteosarcoma	types,	instead,	are	different	in	their	

























Epidemiology:	 High-grade	 osteosarcoma	 is	 the	most	 frequent	 primary	malignant	 tumor	 of	 bone,	
excluding	myeloma.	Its	prevalence	is	of	2-3	cases/million/year	(only	0.2%	of	all	malignancies).	Males	
are	more	commonly	affected	(1.5-2:1).	Most	cases	occur	between	10	and	20	years	of	age	(Figure	2).	
Older	 patients	 are	 usually	 diagnosed	with	 osteosarcoma	 secondary	 to	 radiation,	 Paget	 disease	 of	
bone,	or	develop	chondrosarcomas	or	other	primary	bone	tumors	(2).	
Localization:	70%	of	osteosarcomas	are	localized	around	the	knee	or	shoulder.	Other	locations	are	
proximal	or	mid-femur,	 ilium,	mid	and	distal	 tibia,	proximal	 fibula,	 spine,	 and	exceptionally	 in	 the	
hand	and	foot.	Osteosarcoma	usually	grows	in	the	metaphysis	or	meta-diaphysis	but	tends	to	invade	
the	epiphysis	even	in	presence	of	a	growth	plate	(2).	







Imaging:	 The	 plain	 x-ray	 is	 usually	 diagnostic.	 Typically,	 osteosarcoma	 starts	 intra-medullary,	 but	
breaches	the	cortex	and	expands	in	the	soft	tissues.	It	is	usually	a	combination	of	radiolucency	and	
radiodensity,	sometimes	it	is	entirely	eburneous	with	edges	always	faded.	The	pure	osteolytic	form	
is	 typical	of	 the	 teleangiectatic	variety.	The	 tumor	soft	 tissue	extension	shows	 irregular,	 cloud-like	
radiodensities,	and/or	stripes	of	density	perpendicular	to	the	cortex	(sunray	image).	Occasionally,	it	
is	 purely	 radiolucent	 and	 it	 can	be	appreciated	only	by	CT	and	MRI.	At	 the	periphery	of	 the	area	
where	the	tumor	breaches	the	cortex,	a	triangular	buttress	of	immature	bone	(Codman’s	triangle)	is	
seen.	 This	 is	 due	 to	 reactive	 bone	 acutely	 produced	 by	 the	 periosteum.	 Isotope	 bone	 scan	 is	
intensely	hot	even	beyond	the	radiographic	limits	of	the	tumor.	Rarely,	it	may	reveal	skips	or	distant	































An	endosteal	 and	periosteal	production	of	 reactive	bone	 is	 associated.	Osteosarcoma	may	 invade	







of	 the	 tumor.	 Cells	 are	 large,	 with	 striking	 pleomorphism,	 hyperchromia,	 prominent	 nucleoli,	
frequent	 atypical	 mitoses,	 although	 some	 10%	 of	 cases	 may	 show	 little	 anaplasia	 and	 lead	 to	
confusion	with	benign	entities	 such	 as	 osteoblastoma,	 chondroblastoma,	 giant	 cell	 tumors,	 and	 a	
few	others.	Tumor	osseous	matrix	varies	from	slender	lace-like	seams	of	osteoid	to	islands	or	dense	
sheets	of	woven	bone.	No	regular	trabeculae	rimmed	by	osteoblasts	are	produced	by	osteosarcoma	
cells.	Where	osteosarcoma	 is	 intensely	 sclerotic,	 cells	 are	 scarce,	 small,	with	no	mitoses;	 tissue	 is	
scarcely	 vascular	 and	may	be	necrotic.	 In	 these	areas,	 features	of	malignancy	may	be	absent	and	
diagnosis	of	OS	is	suggested	by	the	permeative	pattern	of	the	tumor.	Occasionally,	osteosarcoma	is	
extensively	 fibro-histiocytic	 (identical	 to	 a	 UPS),	 or	 chondroblastic	 (as	 a	 high-grade	
chondrosarcoma),	or	fibroblastic	(similar	to	a	fibrosarcoma).	The	osteoid-osseous	production,	which	
identifies	 the	osteosarcoma,	may	be	 found	only	 in	 the	microscopic	 study	of	 the	 entire	 specimen.	
Reactive	giant	cells	are	seen,	particularly	in	areas	of	hemorrhage.	Particularly	at	the	periphery	of	the	









1- Sarcomatous	 tissue.	 The	 aspects	 of	 the	 high-grade	 malignancy	 are	 fairly	 evident:	 large,	
pleomorphic	and	hyperchromic	cells	are	seen.	
2- Neoplastic	osteoid	and	osseous	material,	 shaped	with	an	absolutely	anarchical	 architecture.	 It	 is	
nearly	impossible	to	find	trabeculae	bordered	by	a	regular	row	of	osteoblasts.	


























of	metastastic	 disease	 surgery	 and	high-dose	 ifosfamide	 or	 gemcitabine	 and	 taxotere	 have	 been	
used	 (7,8).	 In	 second	 line	 setting,	prospective	 trials	with	agents	 such	as	pemetrexed	or	 sorafenib	
and	 sorafenib/everolimus	 have	 shown	modest	 activity	 in	 osteosarcoma,	 but	 none	 were	 deemed	
worthy	of	further	development	(9-11).		
Prognosis:	 Without	 chemotherapy,	 the	 10-year	 survival	 rate	 is	 10	 to	 15%.	 With	 current	
chemotherapy	 the	 10-year	 survival	 rate	 has	 improved	 to	 about	 70%,	 for	 osteosarcoma	 non-
metastatic	at	presentation	and	involving	the	appendicular	skeleton	(2,12).	Also,	local	recurrence	rate	












wrist,	 shoulder).	 Only	 10%	 within	 a	 joint.	 Usually,	 close	 to	 a	 major	 joint,	 intimately	 related	 to	
tendons,	tendon	sheaths,	bursae,	beyond	the	confines	of	the	joint	capsule.		
Clinical:	 A	 palpable	 deep-seated	 mass,	 often	 with	 pain.	 Pain	 may	 be	 the	 first	 symptom	 of	 the	
disease.	 Tumor	 grows	 slowly	 and	 insiduously	 and	 the	 duration	 of	 symptoms	 ranges	 from	 2	 to	 4	
years,	although	in	some	cases	they	have	been	noted	for	as	long	as	20	years.		
Imaging:	 On	 x-ray,	 a	 round	 or	 oval,	 lobulated	 swelling	 of	 moderate	 density	 near	 a	 joint	 is	 seen.	
Usually,	bone	is	uninvolved.	Periosteal	reaction,	bone	erosion	or	bone	invasion	is	seen	in	a	minority	
of	 patients	 (15-20%).	 Multiple,	 small	 and	 spotty	 calcifications,	 or	 cloudy	 and	 faded	 shadow	 or	
massive	 and	 dense	 radiopacities	 of	 bone	 formation	 (40%).	 Radiopacities	 are	 more	
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frequent	in	the	periphery.	On	angiography,	tumors	are	richly	hypervascularized.	On	CT,	an	infiltrating	
soft	 tissue	mass	 is	 seen,	with	 slightly	higher	density	 than	muscle,	markedly	enhanced,	with	easily	
detected	calcifications,	cortical	erosion,	joint	invasion	when	tendons	or	ligaments	are	involved.		On	
MRI	–	tumors	are	nearly	always	(90%)	hypointense	on	T1,	hyperintense	on	T2,	less	commonly	with	
fluid	 levels	 (15%).	 Marked	 inhomogeneity,	 enhancement	 and	 septation	 are	 seen	 on	 T2.	 A	 triple	
signal	pattern	on	T2	 (30%):	white-like	 fluid,	 gray-like	 fat,	dark-like	 fibrous	 tissue.	 Small	high	 signal	





Radiograph,	 axial	 and	 sagittal	 T1	
and	T2W	FS	MR	 images.	 The	mass	
is	 calcified,	 displaces	 the	 bones,	




surrounding	 tissues,	 from	 yellow	 to	 gray-white.	More	 rapidly	 growing	 lesions	 are	 a	 soft,	 globose	
mass	 poorly	 encapsulated,	 with	 a	 variegated,	 friable	 or	 shaggy	 appearance,	 from	 mottled	 pink	
yellow	to	light	brown,	with	frequent	necrosis,	hemorrhage	and	cystic	areas.	Calcifications	are	rarely	
seen.	Two	different	types	of	cells	are	seen:	epithelial	and	spindle	cells,	in	four	patterns:	1)	biphasic	
type:	 two	 cellular	 components;	 2)	 monophasic	 fibrous	 type:	 only	 spindle	 cells;	 3)	 monophasic	





cystlike	 spaces	with	 granular	 or	 homogeneous	 secretions.	 Fibrous	 cells	 are	well-oriented,	 plump,	
spindle-shape,	 have	 a	 uniform	 appearance,	 with	 scant	 and	 indistinct	 cytoplasm	 and	 oval,	 dark	
nuclei.	They	form	solid,	compact	masses	with	irregular	nodular	arrangement.	A	fine	net	of	collagen	
fibers	surrounds	the	single	cells	of	the	fibrous	component.	Mitotic	figure	are	infrequent	(1).		




lesion	 and	 only	 a	 minute	 focus	 of	 epithelial	 cells	 may	 be	 observed.	 Monophasic/epithelial	 type	
synovial	sarcoma	is	rare	and	presents	a	pseudoglandular	feature	with	poorly	developed	spindle	cells	
pattern	 prevalence.	 In	 poorly	 differentiated	 synovial	 sarcoma	 there	 are	 solidly,	 packed,	 oval	 or	
spindle,	poorly	differentiated	cells;	cells	are	usually	small	in	size	and	appear	neither	clearly	fibroblast	
nor	epithelioid	cell.	Mitotic	 figures	are	 frequent,	 richly	vascularized	with	hemangiopericytoma	 like	
pattern.	 Biphasic	 synovial	 sarcoma	 usually	 does	 not	 require	 immunohistochemistry	 for	 diagnosis.	
Monophasic	and	poorly	differentiated	synovial	sarcoma	show	cytokeratin	expression	in	most	cases,	
although	 it	 can	 be	 quite	 focal	 and	 confined	 to	 only	 rare	 cells	 in	 an	 entire	 section.	 EMA	may	 be	
positive	 in	 some	 cytokeratin-negative	 cases.	 S-100	protein	 expression	 is	 present	 in	 20%	of	 SS	 but	
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CD34	expression	 is	not	seen.	More	than	70%	of	synovaial	sarcomas	are	CD99	positive,	particularly	
the	 poorly	 differentiated	 asynovial	 sarcoma.	 There	 is	 nuclear	 expression	 of	 TLE-1.	 The	 balanced	
reciprocal	translocation	t(X;18)(p11.2;q11.2)	is	found	in	more	than	90%	resulting	in	fusion	of	the	SYT	
gene	on	chromosome	18	with	the	SSX1,	SSX2,	or	rarely	SSX4	gene	on	the	X	chromosome	(15).		
Course	 and	 Staging:	 Local	 recurrence	 is	 common	 even	 10	 years	 later	 if	 inadequate	 surgery	 was	
performed.	Metastases	develop	in	about	50%	of	cases.	The	tumor	usually	presents	as	AJCC	stage	IIB	
(15).			
Treatment:	 Surgery	 aims	 at	 obtaining	 wide	 margins,	 also	 sacrificing	 functionally	 important	
structures	or	amputating	the	limb.	Wide	conservative	surgery	may	be	difficult	for	the	characteristic	
growth	 of	 the	 tumor	 (16).	 It	 may	 be	 useful	 to	 associated	 adjuvant	 chemotherapy	 and	 pre-	 or	
postoperative	radiation	therapy.	Excision	of	the	regional	lymph	nodes	can	be	considered	for	selected	
patients;	sentinel	node	biopsy	may	be	worthwhile	in	slected	patients.	Overall	10-year	survival	varies	
from	 15	 to	 35%.	 Favorable	 prognostic	 factors	 are:	 <5cm,	 youth,	 women,	 distal	 extremities,	
calcifications,	<15	mits/10HPF,	degree	of	glandular	differentiation,	no	intravascular	plugs	(16).		
In	patients	with	recurrent	disease,	the	post-	relapse	survival	is	very	poor,	with	a	5-year	OS	of	about	
20–30%	 after	 lung	 recurrence,	 and	 very	 few	 patients	 live	 after	 3	 years	 in	 case	 of	 multiple	 site	
recurrences	(12,	16).	No	standard	treatment	strategies	are	defined	in	this	setting,	due	to	the	scanty	
literature	on	this	specific	subject		(17).	
Nonetheless,	 Karavasilis	 et	 al.	 (18)	 in	 a	 series	 of	 488	 advanced	 STS,	 including	 SS,	 concluded	 that	
palliative	 chemotherapy	 should	 be	 regarded	 as	 a	 standard	 treatment	 option,	 with	 approximately	
half	of	patients	deriving	benefit.		
New	target	have	been	explored	 in	 synovial	 sarcoma,	but	only	 the	pazopanib	 study	 (PALETTE)	 (19)	
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immunity	 consists	 of	 humoral	 and	 cell- mediated	immunity.		
Innate Immunity Adaptive Immunity 
TWO ARMS OF THE IMMUNE SYSTEM 






T	 lymphocytes	 recognize	 short	 peptides	 as	 antigens	 presented	 by	 major	 histocompatibility	
complexes	 (MHCs)	 on	 the	 cell	 surface	 of	 DCs	 (21).	 CD8	 and	 CD4	 T	 cells	 recognize	 antigen	 in	 the	
context	of	MHC	class	I	and	class	II	molecules,	respectively.	Primed	and	activated	T	cells	differentiate	





























Adaptive	 focal	expression	of	PD-L1	by	macrophages	 (CD68+/CD163+)	occurs	at	 the	 interface	of	 tumor	cell	nests	with	
immune	infiltrates	secreting	pro-inflammatory	factors	such	as	interferon-γ.	The	ligation	of	PD-L1	on	macrophage	and,	in	
some	 histotypes,	 on	 tumor	 cells,	with	 programmed	 cell	 death	 protein	 1	 (PD-1)	molecules	will	 down-modulate	 T	 cell	




tumour.	 It	 is	 well	 established	 that	 chronic	 inflammation	 and	 the	 presence	 of	 M2	 macrophages	
favour	 tumour	 growth	 and	 spreading	 (24).	 Lymphocytes	 are	 not	 randomly	 distributed	 but	 are	
located	 in	 specific	areas.	Therefore,	NK	cells	are	 found	 in	 the	stroma	and	are	not	 in	contact	with	
tumour	cells.	B	cells	are	mostly	found	in	the	invasive	margin	of	growing	tumours	and		in	TLS	that	are	
particularly	 CD8+	 T	 cells,	may	 be	 located	 in	 the	adjacent	 to	 tumour	 beds	 (25).	 T	 cells,	
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invasive	margin	but	can	also	be	in	the	tumour	core.	Immature	dendritic	cells	are	distributed	in	the	




may	have	different	 roles	 in	 tumour	 control.	Moreover,	 the	variable	density	and	 location	of	 these	







During the past decade, work that began 
with the mouse studies by R. D. Schreiber 
and colleagues1–4, and that culminated with 
the demonstration that infiltrating T cells 
have a major effect on the clinical attributes 
of human cancer5,6, has changed the field of 
tumour immunology. Indeed, a recent 
review by Hanahan and Weinberg included 
“avoiding immune destruction” (REF. 7) as 
an emerging hallmark of cancer, in addi-
tion to the previously established hallmark 
of tu our-promoting inflammation. The 
potential effect of a patient’s immune system 
on clinical outcome is not only of academic 
inter st but it also has important implica-
tions for the identification of prognostic 
markers, and markers that predict responses 
to chemotherapy and radiotherapy.
A demonstration of the effect of the host 
immune response on tumour invasion, 
recurrence and metastasis has come from 
analyses of the in situ immune components 
and how these are organized within human 
tumours. Indeed, immune infiltrates ar  
heterogeneous between tumour types, and 
are very diverse from patient to patient. 
All immune cell types may be found in a 
tumour, including macrophages, dendritic 
cells, mast cells, natural killer (NK) cells, 
naive and memory lymphocytes, B cells and 
effector T cells (including various subsets  
of T cell: T helper cells, T helper 1 (TH1) cells, 
TH2 cells, TH17 cells, regulatory T (TReg) cells, 
T follicular helper (TFH) cells and cytotoxic 
T c lls). These immune cells can be located 
in the core (the centre) of the tumour, in the 
invasive margin or in the adjacent tertiary 
lymphoid structures (TLS). The analysis of the 
location, density and functional orientation 
of the different immune cell populations 
(which we have termed the ‘immune contex-
ture’ (REF. 8)) in large annotated collections 
of human tumours has allowed the identifi-
cation of components of the immune con-
texture that are beneficial, as well as those 
that are deleterious, to patients. In addition, 
bioinformatics tools9,10 have permitted the 
identification of chemokines and cytokines 
that are involved in shaping the immune 
contexture11.
The immune contexture: characteristics
Histopathological analyses of human 
tumours have provided evidence that vari-
able numbers of infiltrating immune cells  
are found in different tumours of the same 
type, and are found in different locations 
within and around a tumour (FIG. 1). Macro-
phages, mast cells, granulocytes and myeloid-
derived suppressor cells (MDSCs) are found 
in most cases infiltrating or surrounding 
tumour beds both in the core and at the 
nvasive front of the tumour. It is well estab-
lished that chronic inflammation and the 
presence of M2 macrophages favour tumour 
growth and spreading12. Lymphocytes are 
not randomly distributed but are located in 
specific areas. Therefore, NK cells are found 
in the stroma and are not in contact with 
tumour cells. B cells are mostly found in the 
invasive margin of growing tumours and 
in TLS that are adjacent to tumour beds13. 
T cells, particularly CD8+ T cells, may be 
located in the invasive margin but can also 
be in the tumour core. Few CD8+ T cells are 
seen in TLS, which are similar to secondary 
follicles in lymph nodes that contain naive 
T cells and memory T cells, B cells and mature 
dendritic cells. Indeed, immature dendritic 
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CD3+CD8+ effector T cells with cytotoxic granules that 
contain perforin and granzymes, which are released on 
interaction with target cells expressing cognate antigen. 
This leads to the death of target cells by apoptosis.
Dendritic cells
Cells that capture microorganisms or dead tumour cells 
and that process them to present antigen to T cells in 
secondary or tertiary lymphoid organs. They express high 
levels of co-stimulatory molecules, which allows them to 
activate naive T cells.
High endothelial venules
Specialized venules that occur in secondary lymphoid 
organs, except the spleen. They allow continuous 
transmigration of lymphocytes as a consequence of the 
constitutive expression of adhesion molecules and 
chemokines at their luminal surface.
Macrophages
Can be subdivided according to their cellular properties 
and cytokine secretion profiles. M1 macrophages secrete 
pro-inflammatory cytokines (IL-1, IL-6 and TNF), release 
reactive oxygen and reactive nitrate species and have a 
pro-inflammatory role. M2 macrophages secrete IL-4, 
IL-10, IL-13 and TGFβ and have an anti-inflammatory role, 
promote angiogenesis and favour tumour progression.
Memory T cells
CD3+CD4+CD45RO+ and CD3+CD8+CD45RO+ cells that 
have encountered antigen and that respond faster and with 
increased intensity on antigenic stimulation compared  
with naive T cells.
Myeloid-derived suppressor cells
(MDSCs). Heterogeneous population of polymorphonuclear 
and monocytic CD11b+GR1+ cells that inhibit T cell 
activation.
Naive T cells
CD3+CD4+ and CD3+CD8+ cells that differentiate into 
effector T cells (CD4+ T helper cells or CD8+ cytotoxic 
T cells) in secondary lymphoid organs or TLS after 
stimulation with three signals: antigen, co-stimulatory 
molecules and cytokines.
Regulatory T (TReg) cells
Population of CD3+CD4+ T cells that inhibit effector B and 
T cells. Some produce cytokines with immunosuppressive 
activities; for example, IL-10 and TGFβ. They have a central 
role in suppressing anti-self immune responses to prevent 
autoimmune diseases.
Tertiary lymphoid structures
(TLS). Ectopic lymphoid aggregates that are generated 
during the process of chronic immune stimulation and  
that exhibit the structural characteristics of secondary 
lymphoid organs.
T helper cells
Populations of CD3+CD4+ effector T cells that secrete 
cytokines with differential activities. TH1 cells produce IL-2 
and IFNγ and favour cellular immunity (acting on CD8+ 
cytotoxic T cells, NK cells and macrophages). TH2 cells 
produce IL-4, IL-5 and IL-13 and favour humoral immunity 
(acting on B cells). TH17 cells produce IL-17A, IL-17F, IL-21 
and IL-22 and favour anti-microbial tissue inflammation 
(acting on epithelial and endothelial cells, fibroblasts and 
immune cells).
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1863	 (26).	Today,	we	are	 still	unravelling	 the	complexities	of	 the	 interaction	between	cancer	and	
the	 host	 immune	 system.	 Different	 components	 of	 the	 immune	 system	 can	 either	 promote	 or	
combat	 tumour	 growth.	 The	 potential	 for	 the	 immune	 system,	 in	 particular	 CD8+	 cytotoxic	 T	
lymphocytes,	to	control	or	eradicate	tumours	has	been	shown	in	 laboratory	models.	 In	a	study	of	
human	colorectal	carcinoma	(CRC)	specimens	detailing	the	relationship	between	T	cell	densities	at	
the	 invasive	 tumour	 margin	 and	 those	 in	 the	 centre	 of	 the	 tumour,	 high	 densities	 of	
CD3+CD8+CD45RO+granzyme+	 T	 cells	 (that	 is,	 antigen-experienced	 cytolytic	 Teff	 cells)	 were	
associated	with	a	lower	likelihood	of	tumour	relapse	and	improved	overall	survival	(27).	Moreover,	
coordinated	 pathological	 analysis	 of	 CD3+	 T	 cell	 densities	 outperformed	 internationally	 accepted	
clinical	 staging	 criteria	 (Union	 for	 International	Cancer	Control	 (UICC)-TNM)	 in	predicting	disease-
free	 survival	 and	overall	 survival	 in	multivariate	analysis	 (27).	 In	a	 survey	of	 the	 literature	on	 the	
prognostic	importance	of	T	cell	infiltrates	in	different	tumour	types,	the	association	of	CD8+		T	cells	
with	improved	prognosis	was	seen	in	97%	(58/60)	of	the	reports	analysed	(28).			
Table	 1	 summarizes	 the	 effect	 of	 T	 cells	 on	 solid	 tumor	 clinical	 outcome	 (29-53).	 A	 strong	
lymphocytic	 infiltration	 has	 been	 reported	 to	 be	 associated	 with	 good	 clinical	 outcome	 in	many	
different	 tumour	 types,	 including	 melanoma,	 and	 head	 and	 neck,	 breast,	 bladder,	 urothelial,	
ovarian,	colorectal,	renal,	prostatic	and	lung	cancer.	




































Beyond	 enumerating,	 localizing	 and	 phenotyping	 CD8+	 Teff	 cells	 and	 other	 tumour-infiltrating	




other	 non-malignant	 cell	 types	 in	 an	 inflammatory	 microenvironment,	 as	 part	 of	 a	 physiological	
process	to	down-modulate	ongoing	host	immune	responses	in	peripheral	tissues	(52-57).	However,	
tumour	cells	and	associated	stromal	cells	can	also	express	PD-L1,	thereby	turning	off	Teff	cells	(56).	
In	 some	 cancers,	 PD-L1	 expression	 is	 constitutively	 driven	 by	 aberrant	 signalling	 pathways	 or	
chromosomal	alterations.	For	example,	PTEN	mutations	causing	PI3K–AKT	pathway	activation	 in	a	
subset	of	 glioblastoma	 cases	 (58),	 	 can	 result	 in	broad	expression	of	 PD-L1	on	 the	 surface	of	 the	
majority	of	the	tumour	cells.		
PD-L1	may	also	be	expressed	in	the	TME	by	a	mechanism	termed	adaptive	immune	resistance	(59)	a	
phenomenon	 in	 which	 tumour	 and	 stromal	 cells	 adapt	 to	 attack	 from	 infiltrating	 T	 cells	 by	
expressing	 the	 immune	 inhibitory	 ligand	 PD-L1.In	 this	 scenario,	 PD-L1	 expression	 is	 driven	 by	
inflammatory	cytokines	such	as	interferon-γ	secreted	by	tumour	antigen-specific	T	cells.		
The	first	scientific	support	 for	 the	concept	of	adaptive	 immune	resistance	was	provided	by	Taube	
and	 colleagues	 in	 a	 study	 focused	 on	 human	melanoma	 samples	 (60).	 In	 this	 study,	 four	 distinct	
archetypes	of	tumour–host	 interaction	were	demonstrated:	1)	broad,	constitutive	tumour	cell	PD-
L1	 expression	 in	 the	 absence	 of	 a	 substantial	 host	 immune	 response,	 consistent	 with	 the	 afore	
mentioned	 genetically	 driven	 constitutive	 PD-L1	 upregulation;	 2)	 PD-L1	 expression	 focally	 and	
geographically	 associated	 with	 the	 host	 anti-	 tumour	 immune	 response;	 3)	 tumours	 that	 had	
immune	cell	 infiltrates	but	 lacked	PD-L1	expression;	and	4)	 tumours	 that	 lacked	both	an	 immune	
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response	and	PD-L1	expression.		
Notably,	 intratumoural	 PD-L1	 expression	 was	 associated	 with	 improved	 overall	 survival	 in	 this	
melanoma	 study,	 contrary	 to	expectations	based	on	 its	 known	 immunosuppressive	 function	 (60).	
This	 paradox	 is	 explained	 by	 a	 mechanism	 in	 which	 cytotoxic	 T	 lymphocytes	 upregulate	 PD-1	
expression	when	they	encounter	tumour	antigens	(adaptive	response	to	IFNγ):	PD-L1	in	this	context	
may	be	considered	as	a	marker	of	active	immune	response.		
Further	 complexity	 has	 arisen	 with	 regard	 to	 the	 cell	 type	 (or	 types)	 expressing	 PD-L1.	 Certain	
cancers,	such	as	melanoma,	SCCHN,	and	breast	cancer,	frequently	express	PD-L1	on	the	surface	of	
tumour	cells	as	well	as	on	 infiltrating	 immune	cells	 (60-62).	 In	contrast,	 in	other	 tumours	such	as	






105	 soft	 tissue	 sarcoma	 patients	 with	 localized	 disease	 (67).	 PD-1	 expression	 was	 measured	 in	
lymphocytes	and	PD-L1	in	tumor	cells.	Interestingly,	the	authors	found	a	significant	correlation	with	














series	of	38	osteosarcoma	patients	with	 localized	and	metastatic	disease	 (70).	 In	 this	study	PD-L1	
gene	expression	by	RT-PCR	assay	was	performed	on	 total	 RNA	of	 the	 same	 samples:	 the	median	
overall	 survival	 for	 PDL1-low	 patients	 was	 89	 months	 (29	 cases),	 and	 28	 months	 for	 PDL1-high	
patients	 (9	 cases)	 (P	 =	 0.054)	 (70).	 Another	 study	 on	 localized	 and	 metastatic	 osteosarcoma	





absent	 in	conventional	 (n	=	119),	mesenchymal	 (n	=	19)	and	clear	cell	 (n	=	20)	chondrosarcomas,	
while	 9/22	 (41%)	 dedifferentiated	 chondrosarcomas	 displayed	 PD-L1	 positivity:	 PD-L1	 expression	
was	not	prognostic	in	this	series	(71).	
2.4	-	VEGFR,	neoangiogensis	and	immunotherapy	
The	 dynamic	 interactions	 between	 tumour	 cells	 and	 immune	 cells	 are	 dependent	 on	 the	 local	
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network	of	blood	and	lymphatic	vessels.	A	dense	vascular	network	may	allow	potential	metastatic	
cells	 to	 escape	 the	primary	 tumour	but,	 conversely,	 could	 also	 favour	 the	 infiltration	by	 immune	
cells	 provided	 that	 the	 relevant	 chemokines	 are	 produced.	 Vascular	 endotheial	 growth	 factor	 A	





Angiogenesis	 is	 involved	 in	 tumor	development	 from	the	 initial	 stages	of	cancer	 formation	 to	 the	
growth	of	distant	metastases.	Importantly,	VEGF	is	overexpressed	not	only	by	tumor	cells,	but	also	
by	 any	 hypoxic	 cells	 in	 the	 tumor,	 including	 tumor	 stromal	 cells,	 fibroblasts,	 and	 macrophages,	
which	are	particularly	responsive	to	hypoxia	(72).	A	tumor	that	is	not	yet	hypoxic	is	usually	avascular	
and	dormant.	When	it	undergoes	the	“angiogenic	switch,”	VEGF	expression	is	elevated,	vasculature	
is	 established	 via	 capillaries,	 and	 the	 tumor	 begins	 an	 exponential	 growth	 phase.	 This	 phase	 is	
associated	with	greatly	increased	metastatic	potential	because	platform	metastasis	can	easily	occur	
via	the	newly	generated	blood	vessels	(72).	
VEGF	 is	also	 important	 in	the	metastatic	process.	When	tumor	cells	gain	entry	 into	blood	vessels,	
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they	travel	to	other	tissues	and	form	metastatic	nodules.	However,	these	nodules	are	initially	poorly	
vascularized	 until	 they	 undergo	 a	 similar	 angiogenic	 switch,	 when	 they	 develop	 vasculature	 and	
start	 to	 grow	 exponentially.	 Anti-VEGF	 monoclonal	 antibodies	 have	 been	 developed	 that	 target	
VEGF-D,	VEGF-C,	and	VEGF	receptors	(VEGFR).	Anti-VEGFR	antibodies	are	currently	in	phase	I	and	II	
clinical	trials,	and	anti-VEGFR3	antibodies	appear	to	inhibit	some	forms	of	angiogenesis.	






















This	 compound	 has	 been	 also	 shown	 effective	 in	 soft	 tissue	 sarcomas,	 with	 partial	 responses	
described	 in	 synovial	 sarcomas,	 leiomyosarcoma,	 angiosarcoma	 (77)	 and	 activity	 described	 for	
desmoplastic	 sarcomas	 (78),	 alveolar	 soft	 part	 sarcomas	 (79)	 and	 extraskeletal	 myxoid	
chondrosarcomas	 (80).	 There	 are	no	published	 studies	 on	 the	use	of	 sunitinib	 in	 bone	 sarcomas,	
with	 limited	 pre-clinical	 evidence	 of	 sunitinib	 potential	 for	 effective	 treatment	 of	 metastasizing	
osteosarcoma	(81).	
Sunitinib	 might	 exert	 immunostimulatory	 activity	 through	 the	 modulation	 of	 the	 ratio	 of	
immunostimulatory	 versus	 immunoregulatory	 cells.	 In	 fact,	 In	 addition	 to	 its	 pro-angiogenic	
function,	 VEGF	 has	 immune	 modulating	 properties,	 which	 include	 increasing	 the	 influx	 of	
lymphocytes	and	DCs	into	the	tumour,	while	decreasing	the	intratumoural	frequencies	of	TReg	cells	
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and	 myeloid-derived	 suppressor	 cells	 (MDSCs)	 (82-84).	 Furthermore,	 high	 expression	 of	 VEGFA	
counteracts	the	beneficial	effects	of	TH1	cells	or	cytotoxic	T	cells	by	suppressing	the	expression	of	
interferon	regulatory	factor	1	(IRF1)	and	granulysin	(GNLY),	respectively	(85).	In	addition,	VEGFA	is	
known	to	 inhibit	dendritic	cell	maturation,	which	may	result	 in	the	 induction	of	suppressor	rather	
than	of	 effector	 cells,	which	 hampers	 the	 necessary	 balance	 of	 immune	 cells	 at	 the	 tumour	 site.	
Indeed,	 treatment	 with	 anti-VEGFA	 chemotherapy	 drugs,	 such	 as	 sunitinib,	 sorafenib	or	
bevacizumab,	 results	 in	 a	 decrease	 of	 TReg	 cells	 and	 MDSCs	 both	 in	 the	 periphery	 and	 in	 the	
tumours	of	some	patients	(86).	The	analysis	of	a	cohort	of	patients	with	metastatic	renal	cell	cancer	































Historically,	 Coley	 reported	 a	 case	 of	 unresectable	 small-cell	 sarcoma	 of	 the	 neck	 in	 1891.	 The	
sarcoma	 completely	 regressed	 after	 a	 severe	 episode	 of	 erysipelas.	 He	 reported	 that	 a	 systemic	
response	against	erysipelas	influenced	the	patient's	tumor	(97).	The	mechanism	by	which	erysipelas	
caused	tumor	regression	was	unclear	at	that	time.		
However,	 it	 is	now	understood	 that	 the	activation	of	 innate	 immunity	 through	Toll-like	 receptors	
(TLRs)	by	erysipelas	followed	by	activation	of	acquired	immunity	specific	to	sarcoma	may	contribute	
to	the	underlying	mechanism	(98).	Thus,	the	case	described	by	Coley	was	the	first	to	demonstrate	
that	 the	 immune	 system	might	be	 involved	 in	 the	 spontaneous	 regression	of	 sarcomas.	Over	 the	
past	100	years,	his	work	encouraged	many	scientists	to	work	on	cancer	immunology,	in	an	attempt	
to	find	a	cure	for	cancers	(99,	100).	
The	myriad	 of	 genetic	 and	 epigenetic	 alterations	 that	 are	 characteristic	 of	 all	 cancers	 provide	 a	
diverse	 set	 of	 antigens	 that	 the	 immune	 system	 can	 use	 to	 distinguish	 tumour	 cells	 from	 their	
normal	counterparts.		
Tumor	 antigens	 recognized	 by	 the	 immune	 system	 are	 categorized	 into	 cancer	 testis	 antigens	







Because	 tumor	 antigens	 are	 potential	 targets	 that	 induce	 cytotoxic	 immune	 responses,	 many	
clinical	trials	have	utilized	tumor	antigens	as	vaccines	for	decades.		
In	 2011	 Robbins	 et	 al	 published	 the	 first-in-human	 clinical	 trial	 utilizing	 the	 adoptive	 transfer	 of	
autologous	 peripheral	 blood	 mononuclear	 cells	 (PBMC),	 transduced	 with	 a	 high-affinity	 TCR	
directed	 against	 an	 HLA-A*0201–restricted	 NY-ESO-1	 epitope,	 in	6	 cases	 with	 NY-ESO-1	 positive	
synovial	 sarcomas.	 This	 trial	 demonstrated	 a	 good	 response	 in	 terms	 of	 response	 rate	 (102).	
However,	results	are	preliminary	(18	cases	treated	so	far	 in	the	up-date	publication,	103)	and	the	
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Table 1: Cancer testis antigens in bone and soft tissue sarcomas.
Sarcoma subtypes Expression of cancer testis antigens
NY-ESO LAGE MAGE-A3 MAGE-A4 MAGE-A9 PRAME SSX-2
Bone sarcomas
Osteosarcoma [14] + + + +
Ewing’s sarcoma [14] + + + +
Chondrosarcoma [14] + + + +
Soft tissue sarcomas
Synovial sarcoma [15] + + + + + + +
Malignant fibrous histiocytoma,
pleomorphic spindle cell sarcoma [15] + + + + +
Liposarcoma [15] + + + + + +































Figure 1: An overview of tumor immunology. Tumor cells are initially attacked by the innate immune ystem. DC capture tumor antigens
at the tumor site and migrate to the tumor draining lymph nodes. DCs present the tumor antigen to T cells within the lymph node. Antigen-
specific CD4 and CD8 T cells are stimulated by DCs. After stimulation, T cells differentiate into effector cells and activate at the tumor site.
Effector CD8 T cells kill tumor cells, although their function is regulated by the immune check oint m chanism. NK: natural killer cell; MP:
macrophage; DC: dendritic cell.
3. Outcomes of Clinical Trials for Bone and
Soft Tissue Sarcomas
Treatments for bone and soft tissue sarcomas include surgery,
chemotherapy, and radiotherapy. To date, clinical results of
combined therapies have been more successful than those
of surgical approaches. However, as described above, the
prognosis of bone and soft tissue sarcomas has plateaued
since the 1990s. In these recent years, immunotherapies are
expected to further improve the prognosis of patients, and
several clinical trials have been performed (Tables 2 and 3).
3.1. Cytokine Therapies. Cytokines are proteins that regulate
the immune system. Interleukin-2 (IL-2) and interferons
(IFNs) have been used in the immunotherapy for sarcomas
[77], and clinical results are evident. IL-2 leads to the activa-
tion and expansion of CD4 and CD8 T cells [78]. Rosenberg
et al. established a tumor regression model involving recom-
binant IL-2 injection for murine melanoma and sarcomas
[32].Then, several studies described the effectiveness of high-
dose IL-2 therapy for patients with metastatic melanomas
[79, 80]. Therefore, recombinant IL-2 was administered to
patients with bone and soft tissue sarcomas [16]. Schwinger
et al. reported a positive clinical result using a high-dose IL-
2 treatment in two patients with Ewing’s sarcomas and four
patients with metastatic osteosarcomas. Patients had already
been treated with surgery (1–5 times), chemotherapy (7–43
cycles), and radiation therapy (for patients with Ewing’s sar-
coma). Although one patient with metastatic osteosarcoma














protected. The adoptive transfer of an in vitro sensitized autolo-
gous CD4þ T-cell clone that recognized an HLA-DP"04 restricted
NY-ESO-1 peptide mediated regression of metastatic melanoma
in 1 of 9 patients (16, 18). In 2010, we presented preliminary
results of the ﬁrst adoptive cellular immunotherapy trial for solid
cancers to utilize the transfer of autologous PBMC transduced
with a CG-reactive TCR. In that study as well as the current one,
patients received autologous PBMCs that were transduced with a
TCR, termed 1G4-aLY, that possessed a high avidity for the HLA-
A"0201–restricted NY-ESO-1:157-165 epitope (11). Response
rates of 45% and 67% were observed in the initial cohorts of
melanoma and synovial cell sarcoma patients, respectively, all of
whom had progressive disease after extensive prior treatment.
Clinical responses to therapy were not associated with the per-
sistence of adoptively transferred T cells, as determined either
using NY-ESO-1 tetramer binding or antigen-speciﬁc ELISPOT to
evaluate TCRs, although only 6 patients with synovial sarcoma, as
well as 11patientswithmelanoma,were evaluated in the previous
study. The current study was carried out on 18 patients with
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Survival time in months
Melanoma (n = 20)
Synovial cell sarcoma (n = 18)
NY-ESO-1 TCR Protocol 08C0121






Kaplan–Meier curve of overall survival
and progression-free survival. The
overall and progression-free survival of
heavily pretreated patients with
synovial cell sarcoma (A) and patients
with melanoma (B) in response to
therapy with NY-ESO-1 TCR-transduced
T cells is presented.
Robbins et al.
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Cancer,	 are	 able	 to	 deregulate	 the	 expression	 of	 immune-checkpoint	 proteins,	 such	 as	 PD1	
Figure 1. Multiple co-stimulatory and inhibitory interactions regulate T cell responses
Depicted are various ligand–receptor interactions between T cells and antigen-presenting 
cells (APCs) that regulate the T cell response to antigen (which is mediated by peptide–
m jor histocompatibility c mplex (MHC) molecule c mplexes that ar  recognized by the T 
cell receptor (TCR)). These responses can occur at the initiation of T cell responses in 
lymph nodes (where the major APCs are dendritic cells) or in peripheral tissues or tumours 
(where effector responses are regulated). In general, T cells do not respond to these ligand–
receptor interactions unless they first cog ize their cognat  antigen through the TCR. 
Many of the ligands bind to multiple receptors, some of which deliver co-stimulatory signals 
and others deliver inhibitory signals. In general, pairs of co-stimulatory–inhibitory receptors 
that bind the same ligand or ligands — such as CD28 and cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4) — display distinct kinetics of expression with the co-
stimulatory receptor expressed on naive and resting T cells, but the inhibitory receptor is 
commonly upregulated after T cell activation. One important family of membrane-bound 
ligands that bind both co-stimulatory and inhibitory receptors is the B7 family. All of the B7 
family members and their known ligands belong to the immunoglobulin superfamily. Many 
of the receptors for more recently identified B7 family members have not yet been 
identified. Tumour necrosis factor (TNF) family members that bind to cognate TNF receptor 
family molecules represent a second family of regulatory ligand–receptor pairs. These 
receptors predominantly deliver co-stimulatory signals when engaged by their cognate 
ligands. Another major category of signals that regulate the activation of T cells comes from 
soluble cytokines in the microenvironment. Communication between T cells and APCs is 
bidirectional. In some cases, this occurs when ligands themselves signal to the APC. In other 
cases, activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on 
Pardoll Page 25










(programmed	 cell	 death	 protein	 1)	 and	 its	 ligand	 (PD-L1)	 or	 T-lymphocyte-	 associated	 antigen	 4	
(CTLA-4),	a	protein	receptor	expressed	on	T	cells,	that	downregulates	T	cell	activation.	




In	 the	 last	 years	many	 studies	with	 immune	 checkpoints	 inhibitors	were	 performed	 in	 sarcomas	
with	 pembrolizumab	 (anti-PD1)	 (105),	 which	 was	 considered	 active	 in	 some	 histologic	 subtypes	
(liposarcoma	 dedidiffernetiated	 and	 UPS),	 nivolumab	 (anti-PD-1)	 (combined	 with	 pazopanib,	 an	
anti-VEGFR/PDGFR	in	some	case)	(106)	and	ipilimumab	(anti-CTLA4)	(considered	negative)	(107).		
Last,	CMB305,	a	prime-boost	vaccine	approach	against	NY-ESO-1-expressing	tumors,	was	combined	
with	 anti-PD1	 compound	 (atezolizumab)	 in	 36	 patients	 with	 NY-ESO-1+	synovial	 sarcoma	 or	














connective	 tissue	 and	 extracellular	 matrix,	 altogether	 supporting	 tumour	 structure,	 angiogenesis	
and	growth	(110).	
A	 tumor	 can	 influence	 its	 microenvironment	 by	 releasing	 extracellular	 signals,	 promoting	 tumor	
angiogenesis	 and	 inducing	 the	 inflammatory	 response,	 while	 the	 immune	 cells	 in	 the	
microenvironment	 can	 affect	 the	 growth	 and	evolution	of	 cancer	 cells.	 The	 relationship	between	
cancer	cells	and	their	microenvironment	contributes	to	tumor	heterogeneity		(111).		
Mesenchymal	stem	cells	(MSCs)	are	non-hematopoietic	multipotent	stromal	cells	that	are	involved	
in	 tissue	 homeostasis	 and	 regeneration.	 Early	 studies	 demonstrated	 that	 bone	 marrow-derived	
mesenchymal	 stem	 cells	 (BM-MSCs)	 possess	 a	 remarkable	 ability	 to	 home	 in	 to	 tumor	 sites	 and	
putative	 immune-	 privileged	 status	 that	 renders	 them	 suitable	 carriers	 for	 delivering	 anti-tumor	
agents	to	the	tumor	microenvironment	(112).	However,	BM-MSCs	have	also	been	identified	as	pro-
active	 tumor	 stroma-associated	 cells	 that	 are	 implicated	 in	 promoting	 cell	 survival,	 angiogenesis,	
invasion,	and	metastasis	in	addition	to	the	evasion	of	the	immune	system	(113).		
The	 cross-talk	 between	 tumor	 cells	 and	 stromal	 cells	 induced	 the	 production	 of	 growth	 factors,	


















The	CXCR4/CXCL12	 (SDF-1)	axis	has	additionally	been	 identified	to	have	a	role	 in	normal	stem	cell	
homing.	 	 In	 fact	 BM-MSCs	 express	 CXCR4,	 indicating	 that	 the	 CXCR4/SDF-1	 axis	 may	 direct	 the	
trafficking	 and	metastasis	 of	 these	 cells	 to	 organs	 that	 express	 high	 levels	 of	 SDF-1,	 such	 as	 the	
lymph	nodes,	lungs,	liver,	and	bone	(117).	
High	 levels	 of	 CXCL12	 expressed	 by	 cancer	 cells	 and	 tumor-associated	 stromal	 cells	 directly	
stimulated	 the	proliferation	and	 invasiveness	of	breast	 cancer	 cells	 in	an	autocrine	and	paracrine	
manner	 (118).	 Moreover,	 in	 mouse	 models	 of	 human	 breast	 cancer	 (118),	 and	 prostate	 cancer	
(119),	high	CXCL12	levels	in	the	tumour	attract	CXCR4-positive	inflammatory,	vascular	and	stromal	
cells	 into	 the	 tumour	mass,	 where	 they	 will	 eventually	 support	 the	 tumour	 growth	 by	 secreting	
growth	factors,	cytokines,	chemokines	and	pro-angiogenic	factors.	CXCL12	is	physiologically	mainly	
expressed	 by	 mesenchymal	 stromal	 cells	 in	 various	 organs	 and	 tissues,	 such	 as	 the	 liver,	 lungs,	
lymphatic	tissues	and	bone	marrow	(119).		
Preclinical	 mouse	 models	 of	 human	 multiple	 myeloma,	 acute	 lymphocytic	 leukaemia,	 chronic	




Several	 studies	have	 reported	 that	BM-MSCs	promoted	 the	progression	of	osteosarcoma	through	
different	mechanisms	involving		CXCR4	(121,	122).		Furthermore	a	metanalysis	on	CXCR4	expression	
in	 samples	 of	 patients	 with	 bone	 and	 soft	 tissue	 sarcomas	 was	 recently	 published	 (11	 articles	

























statistical	 analysis	 method	 (multivariate	 analysis	 and	 univariate	 analysis)	 and	CXCR4	measuring	
method	 (IHC	 or	 RT-PCR),	 the	 significant	 correlation	 to	 poor	 overall	 survival	 was	 also	 observed	
except	for	that	in	Ewing	sarcoma	and	RT-PCR	groups	(123).		
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their	 growth	 and	 survival.	 High	 levels	 of	 CXCL12	 secretion	 by	 bone	 marrow	 stromal	 cells	 are	
essential	for	homing	of	CXCR4-expressing	tumor	cells.	CXCR4	antagonists	can	inhibit	the	cross-talk	
between	tumor	and	stromal	cells	and	mobilize	cancer	cells	from	this	protective	microenvironment,	
making	 them	 more	 sensitive	 to	 conventional	 drugs	 (standard	 chemotherapy):	 ‘chemosentitizer	
effect’	(120).	
C.	 High	 expression	 of	 CXCL12	 by	 tumor	 cells	 and	 tumor-associated	 stromal	 cells	 forms	 a	 local	
gradient	of	the	chemokine	in	the	tumor	region.	CXCR4-expressing	bone	marrow	derived	progenitor	







As	 initially	 shown	 in	 an	 acute	 promyelocytic	 leukaemia	mouse	model,	 cancer	 cells	 that	 home	 to	









can,	 directly	 or	 indirectly,	 contribute	 to	 resistance	 to	 chemotherapy	 in	 leukaemia	 (140)	 and	 solid	
tumors	(141).	
Since	 the	 CXCL12-CXCR4	 interaction	 is	 considered	 crucial	 for	 attracting	 tumor	 cells	 to	 the	 bone	
marrow	 niche,	 CXCR4	 inhibitors	 have	 been	 explored	 as	 chemosensitising	 agents	 in	 the	 field	 of	
leukaemia	tretment	(140-142).	
Most	 results	 on	 chemosensitisation	 by	 CXCR4	 inhibition	 have	 been	 obtained	 in	 haematological	
mouse	 models.	 Therefore	 the	 findings	 in	 these	 models	 might	 not	 directly	 be	 applicable	 to	 the	
situation	of	solid	tumours.	Nonetheless,	there	is	growing	evidence	that	CXCR4-positive	solid	tumour	
cells,	 analogous	 to	 leukaemic	 cells,	 also	 interfere	 with	 the	 microenvironment	 that	 favours	 their	
survival	during	anticancer	therapy	(144,	145).	In	an	in	vivo	mouse	model	of	human	melanoma	lung	
metastases,	 the	 CXCR4	 antagonist	 T22	 was	 able	 to	 sensitize	 melanoma	 cells	 for	 immune-
augmenting	low	dose	cyclophosphamide	and	anti-CTLA4	monoclonal	antibody	therapy,	resulting	in	
70	and	50%	 fewer	 lung	metastases,	 respectively,	when	compared	 to	 cyclophosphamide	and	anti-
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CTLA4	monoclonal	antibody	alone	(144).	
In	 conclusion,	 numerous	 preclinical	 studies	 support	 the	 usage	 of	 CXCR4	 antagonists	 in	 cancer,	 in	







The	 overall	 aim	of	 this	 project	 is	 to	 analyse	 current	 evidence	 on	 tumor	microenvironment	 and	











We	 hypothesized	 that	 the	 ability	 of	 PD-1/PD-L1	 immune-checkpoint	 inhibitors	 to	 reduce	 cancer	





Based	 on	 the	 fact	 that	 the	 anti-tumor	mechanism	of	 CXCR4	 inhibitors	 (AMD3100	 and	MDX1338)	
alone	or	 in	combination	with	chemotherapy	were	not	assessed	 in	sarcoma,	we	hypothesized	that	
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AMD3100	 and	 MDX1338	 were	 more	 effective	 than	 chemotherapy	 alone	 in	 the	 treatment	 of	
sarcoma.		
Here,	we	measured	the	expression	of	CXCR4	and	SDF-1	on	osteosarcoma	and	synovial	sarcoma	cell	









After	 EC	 approval,	 tissue	 samples	 obtained	 from	 biopsies	 performed	 prior	 chemotherapy	 in	 129	
patients	 were	 collected.	 Patients	 were	 prospectively	 treated	 at	 Istituto	 Ortopedico	 Rizzoli	 from	
04/2001	 to	 11/2006	 within	 protocol	 ISG-OS1,	 with	 surgery	 and	 a	 chemotherapy	 based	 on	
methotrexate,	cispaltin,	adriamicyn	and	ifosfamide	as	described	(146),	were	collected.	
The	clinical	characteristics	of	the	patients	were	the	following:	the	median	age	was	16	years	(range	
4-39	 years),	 with	 paediatric	 patients	 (59/86,	 67%)	 and	 male	 gender	 (53/86,	 62%)	 being	 most	
represented.	High	LDH	levels	and	high	AP	at	baseline	were	detected	in	36/86	(42%)	and	18/86	(21%)	
of	 patients	 respectively.	 All	 patients	 underwent	 neo-adjuvant	 chemotherapy	 and	 surgery	 as	 per	
protocol.	A	good	pathologic	response	(≥90%	necrosis)	was	achieved	by	45/86	(52%)	of	the	patients.			
All	 samples	 underwent	 decalcification	 as	 previously	 described	 (147).	 For	 tissue	microarray	 (TMA)	
construction,	 a	 slide	 stained	with	 hematoxylin	 and	 eosin	was	 prepared	 from	each	 formalin-fixed,	




From	 TMA	 blocks,	 4	 micron-sections	 were	 cut.	 This	 histological	 sections	 were	 coloured	 with	
haematoxylin	 eosin	 and	 the	 tumor	 microenvironment	was	characterized	by	applying	
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antibodies	 directed	 against	 fixation	 resistant	 epitopes	 of	 CD68	 (tumor	 associated	 macrophages:	
TAM),	CD3,	CD8,	CD20	(T	tumor	infiltrating	lymphocytes:	TILs),	FOXP3	(T	regulatory	lymphocytes:	T-









infiltrates;	 1	 =	 "focal":	 mostly	 perivascular	 in	 tumor	 with	 some	 intra-tumoral	 extension;	 2	 	 =	
antibody	 clone	 Origin	 dilution	 antigen	retrieval	 revelation	system	






















































For	 survival	 analysis	 samples	 were	 classified	 as	 negative	 (immunostaining	 =	 0)	 or	 positive	
(immunostaining	=	1	to	3)	for	all	markers	except:	CD68+	cases	that	were	classified	in	high	expressing	









baseline	 (normal	 vs.	 high),	 pathologic	 response	 (good:	 chemotherapy-induced	 tumor	 necrosis	 ≥	
90%;	 poor:	 chemotherapy-induced	 tumor	 necrosis	 <	 90%)	 (147),	 tumoral	 microenvironment	
components,	PD-1	expression	on	IC,	and	PD-L1	both	on	TC	and	IC.	
In	 the	 analysis	 on	 post-induction	 chemotherapy	 changes,	 CD8	 and	 Tia1	 expression	 were	 with	
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correlated	 with	 OS.	 OS	 was	 estimated	 according	 to	 the	 Kaplan	 and	 Meier	 method	 with	 their	







with	 incomplete	clinical	and	 follow-up	data	were	also	excluded.	General	 informed	consent	 to	 the	
use	 of	material	 was	 obtained	 from	 all	 adult	 patients	 or	 from	 parents/guardians	 for	minors	 from	
2004.	The	research	protocol	was	approved	by	Rizzoli	Orthopedic	Institute	ethics	committee.		
4.1.2.2	-	Data	collection	





The	diagnosis	was	 confirmed	by	pathologists	with	expertise	 in	 soft	 tissue	and	bone	 tumors,	 after	
revision	 of	 histological	 slides	 according	 to	 histopathological	 and	 immunohistochemical	 criteria	





FISH	was	 performed	 using	 the	 SS18(SYT)	 (18q11.2)	 VYsis	 LSI	 Dual	 Color	 Break-apart	 DNA	 probes	
(Abbott	Molecular,	Des	Plaines,	 IL,	USA)	according	 to	 the	manufacturer’s	protocol.	A	minimum	of	
100	tumor	cell	nuclei	with	intact	morphology	as	determined	by	DAPI	counterstaining	were	counted	
in	the	previously	marked	neoplastic	area.	A	positive	result	was	defined	as	the	presence	of	a	visible	






primers	 used	 for	 detection	 of	 t(X;18)	 SS18(SYT)-SSX1	 and	 t(X;18)	 SS18(SYT)-SSX2	 by	 PCR	
amplification	was:	 forward	 SS18	 5ʹGGA	 CAA	GGT	 CAG	 CAG	 TAT	GGA3ʹ;	 reverse	 primers	 for	 SSX1	
5ʹTTG	GGT	CCA	GAT	CTC	TTA	TT3ʹ;	and	reverse	for	SSX2	5ʹTTGGGTCCAGATCTCTCGTG3ʹ	(152).	
4.1.2.6	-	Immunohistochemistry	staining	











and	 young	 adults	 (AYA)	 with < 30	years	 versus	 adults	 with	 ≥30	years);	 tumor	 size	 (≤5	cm	 versus	
>5	cm);	 surgical	 margins	 (adequate	 including	 wide	 or	 radical	 versus	 inadequate	 including	
intralesional,	 marginal	 or	 contaminated	 margins,	 according	 to	 Enneking’s	 classification)	 (153);	
histology	 (biphasic	 versus	 other	 histotypes);	 adjuvant	 treatments	 (chemotherapy	 or	 radiotherapy	
performed	within	3	months	after	 tumor	excision).	Chi-square	 (χ2)	 test	with	Fisher’s	exact	p	value	
was	used	 to	 correlate	 protein	 expression	with	 clinical	 parameters.	Overall	 survival	 (OS)	 time	was	
calculated	from	the	time	of	admission	at	our	 Institute	to	death	or	 last	 follow-up	visit.	All	 time-to-
event	end	points	were	modelled	using	 the	method	of	Kaplan	and	Meier	and	analysed	by	 the	 log-





Peripheral	blood	mononuclear	cells	 (PBMCs)	were	 isolated	 from	buffy	coats	of	healthy	donors	by	
Ficoll-Hypaque	 centrifugation	 (Amersham,	USA).	 CD3+	 and	 CD14+	 cells	were	 purified	 by	magnetic	





(Istituto	 Ortopedico	 Rizzoli,	 Bologna,	 Italy)	 and	 cultured	 in	 Dulbecco's	 modified	 Eagle's	 medium	





CO2.	 ATCC	 synovial	 sarcoma	 cell	 line	 SW982	 was	 purchased	 from	 by	 American	 type	 Culture	




kit	 and	 PDGFR)	 and	 it	 was	 provided	 by	 Pfizer	 Inc,	 NJ,	 USA.	 Axitinib/PF-01367866	 is	 an	 oral	




The	 effects	 of	 Sunitinib	 on	 sarcoma	 cell	 lines	 were	 assessed	 using	 a	 CellTiter	 96®	 AQueous	 One	
Solution	Cell	Proliferation	Assay	(MTS)	–	PROMEGA)	(154).	Cells	at	exponential	phase	were	seeded	
in	 96-well	 plates	 at	 a	 density	 of	 5000	 cells/well	 in	 50	µl	 of	 the	 appropriate	 culture	medium	 and	
incubated	 for	 1	 hour	 at	 37°C	 to	 guarantee	 adherence.	Each	well	plate	was	then	added	with	
		 60	
medium	containing	 sunitinib	 (50	µl)	 at	 different	 concentrations	 (drug	 final	 concentrations:	 0	µM,	
0.5	µM,	1	µM,	3	µM,	5	µM,	7	µM,	10	µM)	and	 for	a	 total	 volume	of	100	µl.	 Each	condition	was	
repeated	in	3	subsequent	well	plates	(1	well	plate	for	24	hours,	1	for	48	hours,	and	1	for	72	hours).	
After	 24	 h,	 48	 h,	 72	 h	 growth,	 the	 cells	 were	 treated	 with	 20μl	 di	 CellTiter	 96®	 AQueous	 One	
Solution	Reagent.	Following	3	h	incubation	(dark	condition)	the	absorbance	at	490	nm	by	a	96-well	





and	 synovial	 sarcoma	 cell	 line	 was	 harvested	 with	 brief	 Trypsin-EDTA	 treatment,	 washed	 in	 and	
centrifuged	 (5	 min/2000	 rpm).	 After	 counting	 the	 cells	 number,	 cell	 lines	 were	 washed	 and	
resuspended	in	phosphate-buffered	saline	(PBS)	solution.	For	PD-L1	staining,	the	mAb	anti-human	
CD274	(B7-H1)	APC-conjugated	(clone	MIH1.		Lot.	E12159-1634;	from	eBiosciences,	San	Diego,	CA)	
was	used.	 (155).	 100.000	 cells	were	 supplemented	with	 3	µl	Anti-Human	PD-L1	 antibody	 and	 re-
suspended	 in	PBS	50	µl.	Cell	were	 incubated	at	4	 °C	 for	20	minutes,	washed	and	 resuspended	 in	
PBS.	At	least	10,000	events	were	collected	from	each	sample	at	FACS	Canto	II	cytofluorimeter.	For	
each	 cell	 line,	 100.000	unstained	 cells	 (autofluorescence)	were	used	as	 a	 control.	 The	number	of	
replicates	(cell	lines	at	subsequent	passages)	was	4.		
4.2.6	-	Mixed	lymphocyte	reaction	(MLR)	
Human	 monocyte-derived	 immature	 dendritic	 cells	 (DCs)	 were	 generated	 by	 a	 6-day	 culture	 of	
CD14+	 cells	 in	 complete	 RPMI	 in	 presence	 of	 granulocyte-macrophage	 colony-stimulation	 factor	
(50 ng/mL;	 GM-CSF	 Endogen,	 USA)	 and	 IL-4	 	 (800 U/mL;	Miltenyi),	 as	 previously	 described	 (156,	
157).		
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also	 characterized	 using	 following	mAbs,	 according	 to	 manufacturer’s	 instructions:	 	 CD3	 APC-H7	











The	 effects	 of	 Sunitinib	 on	 the	 osteosarcoma	 and	 synovial	 sarcoma	 cell	 lines,	 apoptosis	 were	
measured	 using	 flow	 cytometry	 assay.	 After	 cultured	 in	 IMDM	 (or	 DMEM	 for	 Syo	 cell	 line),	 the	
adherent	cells	(150	000/well)	were	cultured	in	the	presence	of	0.5,	1,	3,	5,	7,	10,	12,	15,	20	and	30	






Data	 were	 expressed	 as	 mean	 ±	 standard	 error	 of	 mean	 (SEM)	 of	 values	obtained	 in	 the	
experiments.	 Statistical	 analyses	 were	 performed	 with	 GraphPad	 Prism	 6	 software	 (GraphPad	







Human	 osteosarcoma	 cell	 line	 U2OS	 was	 obtained	 from	 American	 type	 Culture	 Collection	 and	





(Okayama	University,	 Tokyo,	 Japan)	 and	 cultured	 in	 αMEM	 supplemented	with	 10%	 FBS,	 or	 10%	
fetal	calf	serum	(FCS)	and	antibiotics	in	37	C	humidified	atmosphere	with	5%	CO2.	Synovial	sarcoma	
cell	line	SW982	were	purchased	by	American	type	Culture	Collection	and	grown	in	αMEM	10%	FBS,	
100	 U/ml	 penicillin	 and	 100	 μg/ml	 streptomycin.	 The	 cells	 were	 maintained	 in	 a	 humidified	
incubator	in	5%	CO2	at	37	°C.			
Bone	 Marrow	 Mesenchymal	 Stem	 Cells	 (BM-MSCs)	 have	 o	 been	 identified	 as	 pro-active	 tumor	
stroma-	associated	cells	 that	are	 implicated	 in	promoting	cell	survival,	angiogenesis,	 invasion,	and	
metastasis	in	addition	to	the	evasion	of	the	immune	system	(113).	Osteosarcoma	and	synovial	cells	
were	 then	 cultured	 in	 BM-MSCs	 conditioned	 medium	 (BM-MSC–CM),	 containing	 a	 higher	
concentration	of	CXCL12	(SDF-1)	as	compared	to	αMEM	10%FBS,	and	treated	with	CXCR4	inhibitors	
Chemicals	
MDX-1338/	 BMS-936564/	 Ulocuplumab	 s	 a	 fully	 human	monoclonal	 antibody	 specific	 for	 human	
CXCR447Kuhne	MR	and	it	was	provided	by	Bristol	Myers	Squibb	(NYC,	NY,	USA)	(158).	




Bone	marrow	 (BM)	 sample	was	 obtained	 from	 one	male	 patient	 who	 underwent	 surgery	 at	 the	
Rizzoli	 Orthopaedic	 Institute	 after	 informed	 consent	 .The	 isolation	 of	mononuclear	 cells	 and	 the	
expansion	 of	 cultures	 of	 human	 BM-MSCs	 in	 vitro	 were	 performed	 as	 previously	 described,	
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using	 gradient	 separation	 and	 plastic	 adherence	methods	 (159).	BM-MSCs	were	 characterized	 by	
their	 ability	 to	 proliferate	 in	 culture,	 their	 adherent,	 spindle-shape	 morphology,	 their	 ability	 to	
differentiate	 toward	 osteoblastic,	 cartilage	 and	 adipogenic	 lineages	 and	 for	 the	 expression	 of	 CD	
105,	CD73	and	lack	of	CD45	expression.	BM-MSCs,	after	isolation	and	characterization,	were	seeded	
at	 2000	 cells/cm2	 and	 grown	 until	 40-50%	 confluence	 in	 a-MEM	 supplemented	 with	 20%	 FBS.		










Total	 RNA	 was	 extract	 from	 U2OS,	 SW982	 and	 SYO-I	 cell	 lines	 using	 TRizol	 reagent	 (Invitrogen,	
Carlsbad,	CA,	USA),	following	the	manufacturer’s	instructions.	The	concentrations	of	the	total	RNAs	
were	 measured	 using	 a	 spectrophotometer,	 and	 their	 purity	 and	 quality	 were	 checked	 through	
denatured	gel	electrophoresis.	
CXCR4	mRNA	expression	analysis	by	Real	Time	PCR		
mRNA	 levels	 of	 CXCR4,	were	 determined	 in	 osteosarcoma	 cell	 line	U2-OS	 and	 synovial	 sarcomas	
cells	SYO-I	and	SW982	following	TaqMan	Reverse	Transcription	Protocol	 (Applied	Biosystems,	Life	
Technologies,	CA,	USA).	Quantitative	RT-PCR	was	performed	using	Viia7	sequence	detection	system	
(Applied	 Biosystems,	 Life	 Technologies,	 CA,	 USA).		
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t(X;18)	 SS18(SYT)-SSX2	 by	 PCR	 amplification	 was:	 forward	 SS18	 5ʹGGA	 CAA	 GGT	 CAG	 CAG	 TAT	























protocol	 kit	 (MEBCYTO	 Apoptosis	 kit;	 MBL	 International,	 Woburn,	 MA,	 USA),	 the	 adherent	 cells	





The	 number	 of	 viable	 (Annexin−/PI−),	 apoptotic	 (Annexin+/PI−)	 and	 necrotic	 (Annexin+/PI+)	 cells	
were	determined	with	 the	Cell	Quest	 Software	 (BD	Biosciences,	 San	 Jose,	CA,	USA),	using	a	peak	
























Eighty-six	 out	 of	 129	 patients	 with	 localized	 osteosarcoma	 analysed	 had	 evaluable	 results	 for	 at	
least	7	markers	and	were	included	in	the	present	study.		
Most	 of	 the	 cases	 presented	 TILs	 (CD3+	 77/86,	 90%;	 CD8+	 74/86,	 86%,	 CD20+	 25/86,	 29%)	 and	
FOXP3+	population	(Treg)	were	detected	in	28/86	(33%).	Tia-1	was	detected	in	57/78	(73%)	of	the	
samples.	 TAMs	 (CD163	 positive)	 were	 observed	 in	 the	 microenvironment	 in	 47/70	 (67%)	 of	 the	
patients,	while	31/74	(37%)	patients	presented	also	high	 levels	of	CD68	positivity.	Only	3/78	 (4%)	
































Pos	 77	(90)	 74	(86)	 25	(29)	 28	(33)	 57	(73)	 31	(37)	 47	(67)	 3	(4)	 16	(21)	 0	(0)	 19	(22)	 12	(14)	
Neg	 9	(10)	 12	(14)	 61	(71)	 58	(67)	 21	(27)	 53	(63)	 23	(33)	 75	(96)	 62	(79)	 86	(100)	 67	(78)	 74	(86)	
	







Immunohistochemical	 expression	 in	 tumor	 microenvironment	 of	 CD3,	 CD8,	 CD20	 (T	 tumor	 infiltrating	 lymphocytes:	













Figure	 2.	 a)	 5-year	 overall	 survival	 according	 to	 CD8/Tia1	 expression	 at	 diagnosis	 in	 localized	








	 Pts	N.	 %	5-year		OS	 95%	CI	 P-value	
Overall	 86	 74.5	 65-84	 	
Age	 	 	 	 0.9	
		 ≥	18	years	 27	 74	 57-90	 	
		 <	18	years	 59	 75	 63-86	 	
Sex	 	 	 	 0.8	
	 Female	 33	 76	 61-90	 	
	 Male	 53	 74	 61-89	 	
Histologic	Response°		 	 	 	 0.0001	
	 Good	 45	 89	 80-98	 	
	 Poor	 40	 57	 42-73	 	
CD8		 		 	 	 0.003		
Positive	 74	 78	 69-88	 	
Negative	 12	 50	 22-78	 	
TIA-1	°°	 	 	 	 0.008	
		 71	




No	 statistically	 significant	 difference	was	observed	 in	 5-year	OS	 according	 to	 PD-1,	 FOXP3,	 CD68,	
CD20,	Arginase-1,	CD303,	CD163	expression	 in	microenvironment,	 and	age,	 gender	or	 LDH,	while	
PD-L1	 (IC)	 positive	 cases	 had	 a	 non-significant	 inferior	5-year	OS	(PD-L1+	58%	vs	PD-L1-	77%,	p	=	
Moderate	 14	 86	 67-100	 	
Focal	 43	 79	 67-91	 	
None	 21	 52	 31-74	 	
CD8/	Tia1	°°	 	 	 	 0.002	
	 Positive	/	Positive	 57	 81	 70-91	 	
	 Positive	/	Negative	 10	 60	 30-90	 	
	 Negative	/	Negative	 11	 45	 16-75	 	
CD3	 	 	 	 0.07	
	 Positive	 77	 78	 69-87	 	
	 Negative	 9	 44	 12-77	 	
FOXP3		*	 	 	 	 0.13	
		 Positive	 28	 75	 54-93	 	
		 Negative	 56	 73	 64-85	 	
PD-1	(IC)	 	 	 	 0.6	
	 Positive	 19	 74	 54-93	 	
	 Negative	 67	 74	 64-85	 	
PD-L1	(IC)	 	 	 	 0.14	
	 Positive	 12	 58	 30-86	 	
	 Negative	 74	 77	 67-87	 	
LDH	°°	 	 	 	 0.15	
	 Normal	 60	 78	 68-89	 	
	 High	 18	 61	 39-84	 	
sAP	 	 	 	 0.04	
	 Normal	 48	 85	 75-95	 	
	 High	 38	 64	 48-80	 	
Arginase-1	**	 	 	 	 0.3	
	 Positive	 16	 81	 62-100	 	
	 Negative	 61	 70	 59-82	 	
CD303	°°	 	 	 	 0.9	
	 Positive	 3	 67	 13-100	 	
	 Negative	 75	 73	 63-83	 	
CD68	*	 	 	 	 0.1	
	 High	 31	 84	 71-99	 	
	 Low	 53	 67	 54-80	 	
CD163	***	 	 	 	 0.17	
	 Positive	 47	 81	 70-92	 	
	 Negative	 23	 56	 36-77	 	
		 72	
0.14)	(Table	2).		





Since	 PD-L1(IC)	 is	 a	marker	 of	 cytotoxic	 function	 exhaustion,	we	 investigated	 if	 PD-L1	 expression	
could	influence	survival	in	the	subgroup	of	patient	with	CD8+	lymphocytes:	at	univariate	analysis	the	







Variable	 RR	 95%	CI	 P	
CD8/Tia1	 	 	 	
Positive/Positive	 reference	 	 0.05	
Positive/Negative	 1.8	 0.7-5.2	 0.2	
Negative/Negative	 3.1	 1.2-7.8	 0.01	
Histologic	Response	 	 	 	
Poor	 reference	 	 0.007	
Good	 0.27	 0.1-0.7	 	
sPA	 	 	 	
Normal	 reference	 	 0.2	
High	 1.75	 0.8-3.9	 	
Variable	 RR	 95%	CI	 P	









Based	on	multivariate	 analysis	 results	on	pre-treatment	 samples,	 a	post-hoc	analysis	on	CD8	and	
Tia1	 was	 performed.	 Due	 to	 post-treatment	 changes	 33/86	 patients	 were	 assessable	 after	
treatment	(excluding	53	patients	with	massive	necrosis	and	no	tumor).	
Chemotherapy-induced	changes	of	CD8+	TILs	were	as	follow:	all	patients	with	score	0	(5	cases)	were	









Negative	 reference	 	 0.04	
Positive	 2.8	 1-7.4	 	
Histologic	Response	 	 	 	
Poor	 reference	 	 0.02	
Good	 0.3	 0.1-0.9	 	
sPA	 	 	 	
Normal	 reference	 	 0.5	








A	 total	 of	 88	 consecutive	 patients	 were	 selected.	 Forty-five	 patients	 were	 female	 and	 43	 male;	
median	age	was	37	years	 (range	11–63);	14	were	adolescents	and	young	adults	 (AYA)	 (<30	years)	





2	 cases	 surgical	margins	were	 unknown.	 Amputation	was	 performed	 in	 24	 patients	 (27%).	 Forty-
seven	patients	(53%)	underwent	adjuvant	radiotherapy	(RT)	and	57	(65%)	received	chemotherapy:	




























Pos	 79	(96)	 73	(87)	 9	(11)	 2	(2)	 16	(19)	 10	(12)	
















	 Pts	N.	 %	5-year		OS	 95%	CI	 P-value	
Overall	 88	 68	 57-70	 	
Age	 	 	 	 0.003	
		 ≥	30	years	(adult)	 74	 65	 50-78	 	
		 <	30	years	(AYA)	 14	 100	 	 	
Size	(uk	in	4)	 	 	 	 0.4	
	 	<	5	cm	 24	 82	 66-98	 	
	 ≥	5	cm	 60	 67	 53-80	 	
Histology	 	 	 	 0.5	
	 	Biphasic		 30	 67	 53-80	 	
	 	Other	 58	 76	 59-93	 	
Chemotherapy	 	 	 	 0.5	
	 	Yes		 60	 68	 54-81	 	
	 	No	 38	 73	 67-85	 	
CD8	(uk	in	4)	 		 	 	 0.4		
Positive	 73	 66	 53-78	 	
Negative	 11	 72	 44-99	 	
CD3		(uk	in	4)	 	 	 	 0.5	
	 Positive	 79	 67	 55-78	 	
	 Negative	 3	 33	 0-87	 	
FOXP3		(uk	in	4)	 	 	 	 0.9	
		 Positive	 9	 76	 47-100	 	
		 Negative	 75	 65	 53-77	 	
PD-1	(IC)	 	 	 	 0.7	
	 Positive	 16	 63	 37-89	 	
	 Negative	 69	 68	 56-80	 	
PD-L1	(IC)	 	 	 	 0.8	
	 Positive	 10	 66	 33-100	 	
	 Negative	 72	 66	 53-78	 	
PD-L1	(TC)	 	 	 	 NV	
	 Positive	 2	 100	 	 	





























We	 hypothesized	 that	 sarcoma	 cell	 lines	 were	 tolerogenic	 by	 increasing	 PD-1	 expression	 on	
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both	 on	 CD3/CD8	 lymphocytes	 (from	 0.5%	 to	 6.7%)	 (a,	 c)	 and	 on	 CD3/CD4	 lymphocytes	 (from	












The	 ability	 of	 nivolumab	 to	 promote	 T-cell	 response	was	 also	 evaluated	 in	 vitro	 using	 allogeneic	
MLR.	
In	an	allogeneic	MLR,	human	monocyte-derived	immature	dendritic	cells	(DCs)	pulsed	with	SaOS-2	
cell	 line	 lysate	were	 co-cultured	with	 lymphocytes:	 PD-1	 blockade	with	 nivolumab	 systematically	



























































Figure	9.	PD-1	up-regulation	 induced	by	dentritic	 cells	 (CDs)	pulsed	with	osteosarcoma	cell	 line	






We	 used	 sunitinib	 at	 4	 different	 concentrations	 (10	 μM,	 15	 μM,	 20	 μM	 and	 30	 μM).	 Sunitinib	
induced	 dose-dependent	 cell	 death	 as	 demonstrated	with	 Annexin	 test	 in	 osteosarcoma	 (MG-63	
		 86	
and	SaOS-2),	in	synovial	sarcoma	(SYO-1	and	SW982)	(Figure	10).	
Figure	10.	Dose-dependent	 apoptosis	 in	osteosarcoma	 (SaOS-2	 and	MG-63)	 and	 synovial	 sarcoma	
(SW982	and	SYO-1)	cell	lines,	with	red	arrow	showing	for	each	cell	line	a	concentration	of	sunitinib	































Before	 all	 the	 experiments,	 we	 tested	 our	 synovial	 sarcoma	 cell	 lines	 for	 the	 presence	 of	 the	


























Then	 we	 evaluated	 protein	 expression	 of	 CXCR4	 and	 SDF-1	 (CXCR12)	 by	 immunofluorescence	
analysis.	The	three	cell	lines	showed	a	different	distribution	of	expression	(Figure	1-3):		




































































MDX	 and	 AMD3100,	 specific	 chemical	 inhibitor	 for	 CXCR4,	 can	 block	 SDF-1/CXCR4	 signalling	
pathway.	 Our	 goal	 was	 to	 investigate	 whether	 MDX1338/AMD3100	 treatment	 can	 reduce	
osteosarcoma	 (U2OS)	and	 synovial	 sarcoma	 (SW982)	 cell	 viability	 (experiments	on	SYO-1	 synovial	
sarcoma	 cell	 line	 are	 ongoing).	 Secondly,	 we	 evaluated	 if	 the	 combined	 use	 of	 doxorubicin	 and	
CXCR4	inhibitors	could	result	in	additive	or	synergistic	inhibition	effect.		
Synovial	sarcoma	(SW982)	cell	viability	after	CXCR4	inhibitor	treatment	
	SW982	 cells	 responded	 to	 different	 MDX1338	 concentrations	 (0.001	 μg/ml,	 0.005	 μg/ml,	 0.05	
μg/ml),	with	a	small	reduction	of	cell	viability,	reaching	a	cell	death	rate	at	72h	of	22%	with	0.005	
µg/ml	drug	concentration	(Figure	5).	




















































We	 wanted	 to	 verify	 whether	 the	 treatment	 with	 CXCR4	 inhibitors	 might	 be	 able	 to	 change	


















































a	 potent	 chemotactic	 factor	 and	 can	 induce	 directional	 migration	 of	 hematopoietic	 and	 non-
hematopoietic	 cells.	 Wound	 healing	 assay	 at	 different	 time	 points	 (24h,	 48h,	 72h)	 reached	 the	



















The	 effects	 of	MDX1338	 (0.005	 μg	 /ml)	 and	AMD3100	 (30	 μg	 /ml)	 on	 SW982	 cell	 apoptosis	was	
















Finally,	 SW982	and	U2OS	were	exposed	 to	 increasing	doses	of	doxorubicin	 (0.001,	0.005,0.01,0.1	
μg/ml)	 alone	 and	 combined	with	 sub-toxic	 dosed	 of	MDX1338	 (0.005	 μg	 /ml)	 and	AMD3100	 (30	
μg/ml)	for	72h.	Data	demonstrated	that	both	CXCR4	inhibitors	didn’t	change	doxorubicin	activity	in	




































We	 than	 assessed	 if	 there	 was	 synergy	 between	 doxorubicin	 and	 CXCR4	 inhibitors	 in	 term	 of	
apoptosis.	No	 significant	differences	were	 found	 in	U2OS	after	72h	of	 combined	 treatments	with	
respect	 to	 doxorubicin	 alone	 at	 a	 dose	 of	 0.01	 µM,	 while	 when	 the	 dose	 of	 doxorubicin	 was	
increased	 at	 0.05	 or	 0.1	 µM,	 a	 significant	 increase	 of	 apoptosis	 was	 observed	 with	 30	 µM	 of	

































On	 the	 other	 hand,	 when	 synovial	 sarcoma	 SW982	 cell	 lines	 were	 exposed	 to	 doxorubicin	










In	 osteosarcoma,	 wound	 healing	 assay	 at	 different	 time	 points	 (24h,	 48h,	 72h)	 demonstrated	 a	













































collegues	 (161-164),	 and	 that	 culminated	 with	 the	 demonstration	 that	 infiltrating	 T	 cells	 have	 a	
major	effect	on	the	clinical	attributes	of	human	cancer	(165,	166),	has	changed	the	field	of	tumour	
immunology.	 Indeed,	 a	 recent	 review	 by	 Hanahan	 and	 Weinberg	 included	 “avoiding	 immune	
destruction”	as	a	hallmark	of	cancer,	in	addition	to	the	previously	established	hallmark	of	tumour-
promoting	 inflammation	 (113).	 The	 potential	 effect	 of	 a	 patient’s	 immune	 system	 on	 clinical	
outcome	is	not	only	of	academic	interest	but	it	also	has	important	implications	for	the	identification	
of	prognostic	markers,	and	markers	that	predict	responses	to	chemotherapy	and	radiotherapy.		
A	demonstration	of	 the	effect	of	 the	host	 immune	 response	on	 tumour	 invasion,	 recurrence	and	
metastasis	has	come	from	analyses	of	the	in	situ	immune	components	and	how	these	are	organized	
within	human	 tumours	 (25,	27,	29,	30,	33,	34,	37,	39,	42,	44,	46).	 Indeed,	 immune	 infiltrates	are	
heterogeneous	between	tumour	types,	and	are	very	diverse	from	patient	to	patient.		
	
The	 aim	 of	 this	 project	 was	 to	 characterize	 osteosarcoma	 and	 synovial	 sarcoma	 tumor	
microenvironment,	to	assess	how	the	infiltrating	immune	cells	can	affect	the	prognosis	of	patients	
and	 to	 assess	 the	activity	of	 immune	modulating	 (anti-PD-1),	 antiangiogenetic	 (anti-VEGFRs,	 anti-
PDGFRs)	compounds	and	migration	inhibitors	(anti-CXCR4)	in	a	in	vitro	model	of	sarcomas.	
The	 role	 of	 microenvironment	 in	 tumor	 immune	 escape	 is	 well	 recognized.	 Several	 studies	








The	 first	 study	 demonstrating	 the	 association	 between	 CD8	 infiltrate	 and	 cancer	 specific	 survival	
was	 published	 in	 2001	 (39)	 and	 similar	 findings	 were	 subsequently	 confirmed	 among	 many	
histotypes	(see	paragraph	2.2.2.1,	Table	1,	ref	25,	27,	29,	30,	33,	34,	37,	39,	42,	44,	46).	
	
In	 the	 sarcoma	 field	 both	 a	 series	 of	 33	ostesarcoma,	 including	metastatic	 and	 localised	patients	
(52)	and	a	large	soft	tissue	sarcoma	French	study,	including	several	histotypes	and	also	low	grades	
lesions,	failed	to	demonstrate	a	prognostic	role	for	CD8+	lymphocytes	(51).	The	results	of	our	study	
are	 in	 contrast	with	 those	data	 (51,	52);	 in	 fact	a	 strong	advantage	 in	 terms	of	 survival	has	been	
observed	in	patients	with	CD8+	infiltrate.		
	
To	 investigate	 the	differentiation	state	of	 tumor-infiltrating	T	cells,	 tissues	were	analysed	 for	Tia1	
expression,	which	 is	 a	marker	of	 cytotoxic	 function:	 the	prognostic	 significance	of	CD8+	cells	was	
even	more	 relevant	when	 the	 tumor	 infiltrate	was	 characterized	by	 the	 concomitant	presence	of	
Tia1+	 lymphocytes.	 Tia1+	 lymphocytes	might	 represent	 a	more	 efficient	 subset	 of	 CD8+	 effector	
cells,	playing	an	important	role	in	immune-surveillance	of	osteosarcoma	(67).	
	
The	prognostic	 role	of	 cytotoxic	TILs	CD8/Tia1	was	also	 confirmed	after	 induction	 chemotherapy,	







difference	 might	 be	 related	 to	 the	 heterogeneity	 of	 the	 cases	 examined,	 being	 many	 of	 them	
metastatic,	 while	 our	 patients	 all	 had	 localized	 disease.	 In	 fact,	 it	 is	 well	 known	 that	 PD-L1	







multivariate	 analysis	 in	 the	 subgroup	 of	 patients	 with	 CD8+	 immune-infiltrate.	 It	 might	 be	
hypothesised	that	“PD-L1”-mediated	immune-suppression	negatively	influences	CD8+	lymphocytes	
function	 (see	 in	 paragraph	2.2.1	 Figure	 1).	 In	 addition,	 it	was	 shown	 that	 tumor	 response	 to	 PD-
L1/PD-1	 inhibition	 is	 directly	 related	 to	 both	 the	 level	 of	 PD-L1	 expression	 and	 lymphocytic	
infiltration	of	the	tumor	(148,	171	–	173).		
None	of	the	patients	had	PD-L1	on	tumor	cells,	as	shown	for	other	histotypes,	such	as	colon	rectal	
and	 gastric	 carcinoma	 (174,	 175).	 About	 7%	 of	 osteosarcoma	 presented	 PD-L1	 in	 the	 neoplastic	
clone	in	the	study	by	Koirala	et	al	(52),	while	head	and	neck	squamous	cell	carcinoma,	melanoma,	
breast	 and	 kidney	 cancer	 frequently	 express	 PD-L1	 on	 the	 surface	 of	 tumour	 (148,	 176).	 Such	
variable	expression	among	different	studies	may	reflect	 the	variable	susceptibility	of	 tumour	cells	












Our	data	 suggest	a	 role	of	 immune-infiltrate	 in	progression	of	 localized	osteosarcoma,	and	might	
support	 the	 use	 of	 immune-modulating	 agents	 in	 the	 treatment	 of	 this	 tumor.	 Of	 interest,	
mifamurtide,	 a	 modulator	 of	 innate	 immunity,	 which	 increases	 a	 wide	 variety	 of	







cases	 with	 PD-1	 and	 PD-L1	 expression,	 both	 on	 tumor	 and	 on	 immune	 cells,	 and	 high	 CD3/CD8	
expression,	similarly	to	D’	Angelo	et	al.	CD8	TILs	had	not	prognostic	impact	in	our	series,	while	in	the	
sub-group	 of	 patients	 treated	with	 surgery	 and	 no	 adjuvant	 chemotherapy,	 cases	 CD8-	 had	 best	
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outcome	 (all	 alive	 at	 10-years).	 While	 we	 have	 no	 reason	 for	 this,	 similar	 findings	 on	 synovial	
sarcoma	were	recently	published	(180,	181).	The	presence	of	high	levels	of	CD8+	lymphocytes	in	the	
tumor	correlated	with	a	worse	metastases-free	survival	(MFS)	and	showed	a	trend	towards	worse	
EFS	 in	 a	 report	 on	22	 cases	 by	 van	 Erp	AEM	et	 al.	 (180).	 Furthermore,	Nowicki	 et	 al.	 showed	an	







Immunotherapy	 for	 treatment	 of	 cancer	 has	 been	 always	 a	 fascinating	 topic.	 Immune	 cells	 are	
initially	 attracted	 to	 tumor	 cells	 by	 the	 presence	 of	 tumor	 specific	 antigens.	 Cancers	with	 higher	




loss	 of	 both	 p53	 and	 RB	 (183),	 In	 addition,	 33%	 of	 primary	 osteosarcoma	 shows	 evidence	 of	
chromothripsis,	or	chromosome	shattering	(184)	and	over	50%	exhibit	kataegis,	or	localized	areas	of	
hypermutation	(185).	The	high	mutational	load	in	osteosarcoma,	along	with	the	regular	interaction	
between	 immune	 cells	 and	 bone	 cells	 in	 normal	 tissue,	 suggests	 that	 osteosarcoma	 may	 be	 an	





synovial	 sarcoma	positivity	 for	NY-ESO-1,	 PRAME,	MAGEA4	was	 confirmed	 in	 the	majority	 of	 the	
cases	(186).	
	
Although	 previous	 studies	 have	 suggested	 a	 potential	 role	 for	 immune	 cells	 in	 osteosarcoma,	 to	
date	no	study	has	provided	an	in	vitro	model	to	assess	checkpoint	inhibitors	in	sarcoma.	
	
Vascular	endothelial	 growth	 factor	 (VEGF),	 v-akt	murine	 thymoma	viral	oncogene	homolog	 (AKT),	
platelet-derived	 growth	 factor	 (PDGF),	 mitogen-activated	 protein	 kinase	 (MAPK),	 are	 variably	




Sunitinib	 might	 exert	 its	 immunostimulatory	 activity	 through	 the	 modulation	 of	 the	 ratio	 of	
immunostimulatory	 versus	 immunoregulatory	 cells.	 In	 fact,	 In	 addition	 to	 its	 pro-angiogenic	





was	able	 to	 inhibit	proliferation	 in	 synovial	 sarcoma	and	osteosarcoma	cell	 lines,	with	best	 result	





from	 20%	 to	 40%	 for	 synovial	 sarcoma,	 and	 from	 20	 to	 80%	 for	 osteosarcoma.	 It	 was	 recently	
reported	 that	 the	 expression	 of	 programed	 PD-L1	 in	 the	 immune	 component	 increased	 with	
pazopanib	therapy,	while	CD8	expression	decreased	(195).	
	






demonstrate	 dose-dependent	 cell	 death	 in	 osteosarcoma	 cells	 and	 synovial	 sarcoma	 cell	 lines	
treated	with	 sunitinib,	with	 a	 significant	 increase	observed	with	 lower	 concentration	 (10	μM)	 for	
osteosarcoma	 MG-63	 cell	 line	 and	 100%	 apoptotic	 rate	 at	 30	 μM;	 on	 the	 other	 hand	 synovial	





L1-positive	 sarcoma	 cell	 lines	 and	 lymphocyte	we	 induced	 PD-1	 expression	 on	 lymphocyte;	 after	













pazopanib	arm,	while	 in	a	non-inferiority	phase	 II	 trial	 in	 renal	 carcinoma	 (200)	 response	 rates	of	
31%	and	24%	 for	 pazopanib	 and	 sunitinb	 respectively,	were	 reported,	 suggesting	 that	 nivolumab	
might	 me	 synergic	 with	 TKI	 in	 the	 contest	 of	 kidney	 cancer.	 Only	 recently,	 a	 phase	 I-II	 trial	
addressing	the	 impact	of	 immune	modulation	on	the	efficacy	of	sunitinib	via	 its	potential	synergy	
with	anti	PD-1	the	context	of	sarcomas	(https://clinicaltrials.gov/ct2/show/NCT03277924)	and	will	
enrol	soft	tissue	sarcoma	and	bone	sarcomas.	 In	particular,	high	grade	soft	tissue	sarcoma	will	be	
included.	 It	 might	 be	 anticipated	 that	 some	 histotypes	 such	 as	 undifferentiated	 pleomorphic	
sarcoma	 (UPS)	 and	 synovial	 sarcoma	 might	 be	 more	 sensitive	 to	 this	 approach,	 being	 more	
frequently	diagnosed	in	patients	immune-suppressed	due	to	transplant	(201)	and	proven	sensitive	
to	pazopanib	in	the	PALETTE	phase	III	trial	(202).		
The	 rationale	 of	 using	 nivolumab	 in	 bone	 sarcoma	 includes	 anectodal	 report	 of	 spontaneous	
regression	 in	 osteosarcoma	 (203)	 and	 genomic	 instability	 described	 for	 both	 osteosarcoma	 (204)	
and	Ewing	sarcoma	(205,	206).	 It	 is	 in	fact	well	known	that	numeric	alterations	of	the	PD-1	ligand	
loci	 (207),	 higher	 neoantigen	 burden,	 and	 DNA	 repair	 pathway	 mutations	 (208)	 might	 increase	




liposarcoma	 (105).	 Enrolment	 to	 expanded	 cohorts	 of	 those	 subtypes	 is	 ongoing	 to	 confirm	 and	
characterize	the	activity	of	pembrolizumab	in	sarcoma.		
Therefore	 it	 is	 important	 to	 find	way	 to	 enhance	 response	 to	 immune-modulator	 and	 to	 identify	
predictive	factors	of	response.	For	example,	 it	was	demonstrated	that	melanoma	patients	express	
higher	 levels	of	PD-L1	on	circulating	T	 cells	 than	healthy	volunteers,	 and	higher	PD-L1	expression	
together	with	 CD137	 expression	 on	 blood	 CD8+	T	 cells	 predicts	 sensitivity	 to	 the	 combination	 of	
anti-CTLA-4+	anti-PD-1	treatment	(209).	
	
Characterize	 peripheral	 blood	 lymphocytes	 changes	 over	 sunitinb	 and	 nivolumab	 treatment	 and	
studying	 CD8/PD-L1	 co-expression	 might	 help	 to	 guide	 treatment	 in	 this	 difficult	 setting.	 In	 this	
contest,	the	Immune	Biomarkers	Task	Force	of	the	Society	for	Immunotherapy	of	Cancer	(SITC),	an	
international	multidisciplinary	panel	of	 experts,	 proposed	guidelines	on	predictors	of	 response	 to	







Last,	 we	 addressed	 the	 role	 of	 stromal	 cell-derived	 factor	 1	 (SDF-1	 or	 CXCL12)	 and	 its	 receptor	
chemokine	 receptor	 4	 (CXCR4)	 in	 sarcoma	 progression.	 Metastasis	 is	 in	 fact	 a	 highly	 organized	
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process	and	various	molecular	 families	are	 involved	 in	 cancer	metastases	and	with	 tumor-storma	
interactions,	 or	 tumor	 microenvironment	 interaction.	 The	 tumor	 microenvironment	 consists	 of	





involved	 in	 tumorigenicity,	 proliferation,	metastasis	 and	 angiogenesis	 in	multiple	 human	 cancers	
(211-215).			
CXCR4	 antagonist	 can	block	 CXCR4/	 SDF-1	 interaction	 and	has	 been	 shown	effective	 in	 inhibiting	
tumor	cell	metastasis	by	targeting	various	pathways	(140-145,216).	But	there	are	few	studies	about	
the	combined	effect	of	CXCR4	antagonist	and	chemotherapy	on	sarcoma	cells	survival	and	growth.			
To	 confirm	 the	 positive	 effect	 of	 SDF-1-CXCR4	 axis	 on	 sarcoma	 survival	 and	metastasis,	 we	 first	





majority	 of	 samples	 (216),	 while	 it	 confirmed	 other	 recent	 findings	 on	 osteosarcoma	 (217).	 This	
difference	might	reflect	histotype-specific	homing	pathway	and	suggests	that,	unlike	in	sarcomas,	in	
CLL	 the	 activation	 of	 CXCR4	 induced	 by	 CXCL12	 occurs	 either	 by	 cell-cell	 interactions	 with	 non-
leukemia	 CXCL12	 expressing	 cells,	 likely	 located	 in	 lymphatic	 tissues,	 or	 mediated	 by	 soluble	
CXCL12.	 Also,	 inverse	 correlation	 for	 CXCR4	 expression	at	gene	and	protein	level	was	noted,	
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with	osteosarcoma	cell	line	U2OS	presenting	low	expression	of	CXCR4	m-RNA	and	98%	positivity	for	
protein	 FACS	 analysis,	 while	 synovial	 sarcoma	 (SYO-1	 cell	 line)	 presented	 high	 levels	 of	 CXCR-4	
mRNA	and	only	12%	protein	expression.	
Several	studies	have	reported	that	BM-MSCs,	which	are	known	to	be	involved	in	tissue	homeostasis	
and	 regeneration	 can	 be	 recruited	 into	 primary	 tumors	 and	 become	 active	 components	 of	 the	
tumor	 microenvironment,	 such	 as	 cancer-associated	 fibroblasts	 (CAFs)	 (218,219)	 BM-MSCs	
contribute	 to	 tumor	 cell	 growth	and	metastatic	 behavior	 in	 a	 variety	of	 cancers,	 including	breast	
(220),	colon	cancer	(221)	and	osteosarcoma	(222-225).		
In	a	 study	by	Fontanella	et	al,	 the	 role	of	BM-MSCs	 in	promoting	growth,	migration	and	 invasion	






As	 a	 noncompetitive	 CXCR4	 inhibitor,	 AMD3100	 can	 block	 the	 SDF-1-CXCR4	 axis.	 The	 inhibition	
effect	 of	 AMD3100	 on	 migration,	 invasion	 and	 metastasis	 of	 various	 cancer	 cells	 has	 been	
confirmed	by	a	large	amount	of	experimental	researches	(227).	
Ulocuplumab	(BMS-936564)/MDX1338	is	a	first	in	class,	fully	human	IgG4	monoclonal	antibody	that	
has	 been	 engineered	 to	 specifically	 bind	 to	 CXCR4	 (228).	 In	 vitro	 studies	 have	 shown	 that	
Ulocuplumab	 (BMS-936564)	has	 a	potent	 anti-tumor	activity	 in	 established	 tumor	 including	AML,	




Furthermore,	 CXCR4	 expression	 seems	 to	 play	 a	 role	 in	 resistance	 to	 chemotherapy	 in	 synovial	
sarcoma	(124)	and	this	is	the	first	study	addressing	SDF1-CXCR4	axis	role	in	this	histotypes.	
We	speculated	that	AMD3100	and	MDX1338	may	have	strong	activity	in	osteosarcoma	and	synovial	






Combined	 treatment	 with	 doxorubicin	 and	 MDX1338	 /AMD3100	 was	 not	 synergic,	 with	 over-
imposable	curves	in	terms	of	cell	vitality.	
The	apoptotic	 rate	was	no	 significantly	different	after	72h	of	 combined	 treatments	doxorubicin	+	
MDX1338,	with	 respect	 to	 doxorubicin	 alone,	while	 a	 slight	 increase	 only	 after	 doxorubicin	with	
AMD3100	was	observed,	although	this	difference	was	not	significant.	
In	 conclusion,	 our	 results	 showed	 AMD3100/MDX1338	 could	 effectively	 induce	 apoptosis	 and	
inhibition	of	proliferation	and	invasion	of	osteosarcoma	and	synovial	sarcoma	cells.	
When	 combined	 with	 chemotherapy,	 CXCR4	 inhibitors	 did	 not	 increase	 proliferation	 inhibition,	
while	 AM3100	 combined	 with	 doxorubicin	 (not	 MDX1338)	 was	 able	 to	 increase	 apoptosis	 as	
compared	 to	 doxorubicin	 monotherapy	 in	 osteosarcoma	 cell	 lines.	 Also,	 both	 AM3100	 and	
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Among	 several	 CXCR4	 inhibitors,	 Plerixafor	 (AMD3100),	 already	 approved	 for	 poor	 mobilizer	
patients	in	bone	marrow	transplant	program,	has	reached	clinical	testing.		
For	instance,	phase	I-II	trial	with	chemotherapy	combined	with	Plerixafor,	or	other	CXCR4	inhibitors	











In	 conclusion,	 CD8/Tia1	 cytotoxic	 T-lymphocytes	 emerge	 as	 an	 important	 mediator	 of	 the	 anti-
tumor	immune	response.	Also,	this	study	highlights	the	prognostic	role	of	tumor	microenvironment	
in	the	setting	of	localized	osteosarcoma.	The	data	are	intriguing,	but	a	clinical	application	requires	





location	 (invasive	margin	versus	 central	 tumor)	are	ongoing,	 and	an	 international	 consortium	has	










Effort	 to	 better	 combine	 tumor-targeted	 agent	 with	 microenvironment	 target	 drugs	 might	













poor	 response	 to	 preoperative	 chemotherapy	 for	 newly	 diagnosed	 high-grade	
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